CoChat

Nanodiamond Integration into Niosomes as an Emerging and Efficient Gene Therapy Nanoplatform for Central Nervous System Diseases

Open access
AL Qtaish, Nuseibah, Gallego, Idoia, Paredes, Alejandro J., Villate-Beitia, Ilia, Soto-Sánchez, Cristina, Martínez-Navarrete, Gema, Sainz-Ramos, Myriam, Lopez-Mendez, Tania B., Fernández, Eduardo, Puras, Gustavo, Pedraz, José Luis · 2022 · ACS Applied Materials & Interfaces

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Abstract

High Resolution Image Download MS PowerPoint Slide Nanodiamonds (NDs) are promising materials for gene delivery because of their unique physicochemical and biological features, along with their possibility of combination with other nonviral systems. Our aim was to evaluate the biophysical performance of NDs as helper components of niosomes, named nanodiasomes, to address a potential nonviral gene delivery nanoplatform for therapeutic applications in central nervous system (CNS) diseases. Nanodiasomes, niosomes, and their corresponding complexes, obtained after genetic material addition at different ratios (w/w), were evaluated in terms of physicochemical properties, cellular uptake, intracellular disposition, biocompatibility, and transfection efficiency in HEK-293 cells. Nanodiasomes, niosomes, and complexes fulfilled the physicochemical features for gene therapy applications. Biologically, the incorporation of NDs into niosomes enhanced 75% transfection efficiency ( p < 0.001) and biocompatibility ( p < 0.05) to values over 90%, accompanied by a higher cellular uptake ( p < 0.05). Intracellular trafficking analysis showed higher endocytosis via clathrins ( p < 0.05) in nanodiaplexes compared with nioplexes, followed by higher lysosomal colocalization ( p < 0.05), that coexisted with endosomal escape properties, whereas endocytosis mediated by caveolae was the most efficient pathway in the case of nanodiaplexes. Moreover, studies in CNS primary cells revealed that nanodiaplexes successfully transfected neuronal and retinal cells. This proof-of-concept study points out that ND integration into niosomes represents an encouraging nonviral nanoplatform strategy for the treatment of CNS diseases by gene therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acsami.2c02182

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Overview of the components and their disposition in (A) nanodiasomes and (B) niosomes.
Figure 1 Overview of the components and their disposition in (A) nanodiasomes and (B) niosomes.CC BY · PubMed Central
Figure 2 Characterization of formulations and complexes prepared with NDs (nanodiasomes/nanodiaplexes) and without NDs (niosome/nioplexes). (A) Size (bars) and zeta potential (dots). (B) Dispersity values of formulations and complexes. Each value represents the mean ± SD of three measurements. (C) Average size-distribution intensities of nanodiasomes (red line) and nanodiaplexes at different cationic lipid/DNA mass ratios (green, blue and black line for 5/1, 10/1, and 15/1 ratios, respectively). (D) Average size-distribution intensities of niosomes (red line) and nioplexes at different lipid/DNA ratios (green, blue, and black line for 5/1, 10/1, and 15/1 ratios, respectively).
Figure 2 Characterization of formulations and complexes prepared with NDs (nanodiasomes/nanodiaplexes) and without NDs (niosome/nioplexes). (A) Size (bars) and zeta potential (dots). (B) Dispersity values of formulations and complexes. Each value represents the mean ± SD of three measurements. (C) Average size-distribution intensities of nanodiasomes (red line) and nanodiaplexes at different cationic lipid/DNA mass ratios (green, blue and black line for 5/1, 10/1, and 15/1 ratios, respectively). (D) Average size-distribution intensities of niosomes (red line) and nioplexes at different lipid/DNA ratios (green, blue, and black line for 5/1, 10/1, and 15/1 ratios, respectively).CC BY · PubMed Central
Figure 3 Microscopy images of nanodiasomes. (A) TEM image of nanodiasomes. Scale bar: 100 nm. (B) Cryo-TEM images of nanodiasomes; asterisks indicate the aqueous phase. Scale bar: 100 nm. (C) Lipid layer of nanodiasomes (black arrow) with NDs integrated into the lipid structure.
Figure 3 Microscopy images of nanodiasomes. (A) TEM image of nanodiasomes. Scale bar: 100 nm. (B) Cryo-TEM images of nanodiasomes; asterisks indicate the aqueous phase. Scale bar: 100 nm. (C) Lipid layer of nanodiasomes (black arrow) with NDs integrated into the lipid structure.CC BY · PubMed Central
Figure 4 Agarose gel electrophoresis assay. (A) Nanodiaplexes. (B) Nioplexes. Lanes 1–3 correspond to free DNA; lanes 4–6, 5/1 ratio; lanes 7–9, 10/1 ratio; lanes 10–12, 15/1 ratio. Nanodiaplexes and nioplexes were treated with SDS (lanes 2, 5, 8, and 11) and DNase I + SDS (lanes 3, 6, 9, and 12). OC: open circular form; SC: supercoiled form.
Figure 4 Agarose gel electrophoresis assay. (A) Nanodiaplexes. (B) Nioplexes. Lanes 1–3 correspond to free DNA; lanes 4–6, 5/1 ratio; lanes 7–9, 10/1 ratio; lanes 10–12, 15/1 ratio. Nanodiaplexes and nioplexes were treated with SDS (lanes 2, 5, 8, and 11) and DNase I + SDS (lanes 3, 6, 9, and 12). OC: open circular form; SC: supercoiled form.CC BY · PubMed Central
Figure 5 Transfection assay in the HEK-293 cell line 48 h post-transfection with nanodiaplexes and nioplexes. (A) Normalized percentages of EGFP-positive live cells (bars) and cell viability (dots). (B) MFI values. (C) Images showing the EGFP signal and cell integrity in HEK-293 cells transfected with nanodiaplexes and nioplexes at the 5/1 lipid/DNA ratio. Scale bar: 200 μm. Each value represents the mean ± SD of three measurements. ***p < 0.001 and *p < 0.05 for nanodiaplexes vs nioplexes at the same lipid/DNA ratio; #p < 0.001 compared with all conditions.
Figure 5 Transfection assay in the HEK-293 cell line 48 h post-transfection with nanodiaplexes and nioplexes. (A) Normalized percentages of EGFP-positive live cells (bars) and cell viability (dots). (B) MFI values. (C) Images showing the EGFP signal and cell integrity in HEK-293 cells transfected with nanodiaplexes and nioplexes at the 5/1 lipid/DNA ratio. Scale bar: 200 μm. Each value represents the mean ± SD of three measurements. ***p < 0.001 and *p < 0.05 for nanodiaplexes vs nioplexes at the same lipid/DNA ratio; #p < 0.001 compared with all conditions.CC BY · PubMed Central
Figure 6 Cellular uptake of complexes at the 5/1 lipid/DNA ratio, analyzed 4 h after transfection in the HEK-293 cell line. (A) Normalized percentage of FITC-pEGFP positive cells. Each value represents the mean ± SD of three measurements; * p > 0.05 for nanodiaplexes vs nioplexes. (B) Confocal microscopy images showing the cellular uptake of nanodiaplexes and nioplexes. Cell nuclei were colored in blue (DAPI), F-actin in red (Phalloidin), and nanodiaplexes and nioplexes in green (FITC). Scale bar: 50 μm.
Figure 6 Cellular uptake of complexes at the 5/1 lipid/DNA ratio, analyzed 4 h after transfection in the HEK-293 cell line. (A) Normalized percentage of FITC-pEGFP positive cells. Each value represents the mean ± SD of three measurements; * p > 0.05 for nanodiaplexes vs nioplexes. (B) Confocal microscopy images showing the cellular uptake of nanodiaplexes and nioplexes. Cell nuclei were colored in blue (DAPI), F-actin in red (Phalloidin), and nanodiaplexes and nioplexes in green (FITC). Scale bar: 50 μm.CC BY · PubMed Central
Figure 7 Intracellular disposition assay of nanodiaplexes and nioplexes in HEK-293 cells. (A) Qualitative analysis of colocalization by confocal microscopy. Scale bar: 50 μm. (B) Quantitative determination of colocalization by cross-correlation analysis. Data are represented as mean ± SD of three measurements; * p > 0.05 for nanodiaplexes vs nioplexes. (C) Transfection performance after the addition of specific endocytic inhibitors. The values were normalized to the transfection without an inhibitor. ***p < 0.001.
Figure 7 Intracellular disposition assay of nanodiaplexes and nioplexes in HEK-293 cells. (A) Qualitative analysis of colocalization by confocal microscopy. Scale bar: 50 μm. (B) Quantitative determination of colocalization by cross-correlation analysis. Data are represented as mean ± SD of three measurements; * p > 0.05 for nanodiaplexes vs nioplexes. (C) Transfection performance after the addition of specific endocytic inhibitors. The values were normalized to the transfection without an inhibitor. ***p < 0.001.CC BY · PubMed Central
Figure 8 Biological performance of nanodiaplexes and nioplexes in lysosomes of HEK-293 cells. (A) Qualitative analysis of colocalization by confocal microscopy. (B) Quantitative determination of colocalization by cross-correlation analysis. Data are represented as mean ± SD of three measurements; * p > 0.05 for nanodiaplexes vs nioplexes. (C) DNA release profiles evaluated by gel electrophoresis. Lane 1, naked DNA; lane 2, nanodiaplexes incubated with PS; lane 3, nioplexes incubated with PS; lane 4, nanodiaplexes; lane 5, nioplexes. PS refers to phosphatidylserine micelles; OC: open circular form; SC: supercoiled form.
Figure 8 Biological performance of nanodiaplexes and nioplexes in lysosomes of HEK-293 cells. (A) Qualitative analysis of colocalization by confocal microscopy. (B) Quantitative determination of colocalization by cross-correlation analysis. Data are represented as mean ± SD of three measurements; * p > 0.05 for nanodiaplexes vs nioplexes. (C) DNA release profiles evaluated by gel electrophoresis. Lane 1, naked DNA; lane 2, nanodiaplexes incubated with PS; lane 3, nioplexes incubated with PS; lane 4, nanodiaplexes; lane 5, nioplexes. PS refers to phosphatidylserine micelles; OC: open circular form; SC: supercoiled form.CC BY · PubMed Central
Figure 9 GFP expression in embrionary rat CNS primary cells. Neuronal and retinal primary cells transfected with nanodiaplexes (A,C) at the 5/1lipid/DNA ratio and the positive control Lipofectamine 2000 in primary neuronal (B) and retinal cells (D). Cell nuclei were stained with Hoechst 33342 (blue). Scale bar: 50 μm.
Figure 9 GFP expression in embrionary rat CNS primary cells. Neuronal and retinal primary cells transfected with nanodiaplexes (A,C) at the 5/1lipid/DNA ratio and the positive control Lipofectamine 2000 in primary neuronal (B) and retinal cells (D). Cell nuclei were stained with Hoechst 33342 (blue). Scale bar: 50 μm.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 31

Metadata

Authors
AL Qtaish, N., Gallego, I., Paredes, A. J., Villate-Beitia, I., Soto-Sánchez, C., Martínez-Navarrete, G., Sainz-Ramos, M., Lopez-Mendez, T. B., Fernández, E., Puras, G., & Pedraz, J. L.
Affiliations
  • NanoBioCel Research Group, Laboratory of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of the Basque Country (UPV/EHU), Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain
  • University of the Basque Country (ES)
  • Queen's University Belfast (GB)
  • Networking Research Centre of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Institute of Health Carlos III, 28029 Madrid, Spain
  • Universitat de Miguel Hernández d'Elx (ES)
Corresponding author
Puras, Gustavo
Venue
ACS Applied Materials & Interfaces
Published
2022-03-15
Volume
14
Issue
11
Pages
13665-13677
ISSN
  • 1944-8244 (ISSN-L)
  • 1944-8252
OpenAlex
W4220840779
Cited by
29
References
57
Citations by year
2026: 6 · 2025: 3 · 2024: 11 · 2023: 8 · 2022: 1
FWCI
1.87
Type
journal article
Language
en
Open access
Locations
  • ACS Applied Materials & Interfaces (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Communities in ADDI (University of the Basque Country) (submittedVersion, cc-by)
  • Hispana (submittedVersion, cc-by)
  • Research Portal (Queen's University Belfast) (submittedVersion, cc-by)
  • Greater South Information System
Funders
  • Centro de Investigaci?n Biom?dica en Red en Bioingenier?a, Biomateriales y Nanomedicina
  • Eusko Jaurlaritza (IT907-16)
  • Euskal Herriko Unibertsitatea (ESPDOC19/47, PIF17/79)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Physical Sciences › Materials Science › Materials Chemistry › Diamond and Carbon-based Materials Research
Keywords
nanodiamonds, niosomes, non-viral gene delivery, central nervous system disorders, transfection efficiency, cellular uptake, endocytosis, clathrin-mediated endocytosis, caveolae, lysosomal escape, biocompatibility, neurons, retinal cells
MeSH terms
Central Nervous System Diseases, Humans, Liposomes, Plasmids, Genetic Therapy, HEK293 Cells, Nanodiamonds

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.